Neurocrine Biosciences | NBIX - Interest Expense On Debt


Neurocrine Biosciences reported $1.1M in Interest Expense on Debt for its fiscal quarter ending in March of 2024.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
ALKERMES USD 4.65M 1.35M Dec/2024
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amgen USD 653M 32M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Cytokinetics USD 26.32M 2.06M Sep/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 255M 1000K Dec/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Incyte USD 582K 10K Dec/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pfizer USD 711M 59M Dec/2025
Prothena USD 352.63M 46.44M Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Repligen USD 5.41M 60K Sep/2025
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Teva Pharmaceutical Industries USD 220M 17M Dec/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xoma USD 3.4M 150K Jun/2024